Great News! Huluwa Pharmaceutical Group Wins Another Honor, Ranking on the 2025 Hainan Private Enterprises Dual Top Lists!

Recently, the Hainan Federation of Industry and Commerce held a press conference in Haikou announcing the "2025 Top 100 Hainan Private Enterprises and Top 20 Private Enterprises by R&D Investment". Huluwa Pharmaceutical Group ranked 34th among the 2025 Top 100 Hainan Private Enterprises and 5th among the Top 20 in R&D Investment, becoming a vivid example of innovation breakthroughs in Hainan's pharmaceutical industry under the Free Trade Port policies.

As a leading pediatric pharmaceutical company rooted in Hainan, Huluwa Pharmaceutical Group is guided by its mission of "Huluwa, Healthy Chinese Children". Leveraging the advantages of the Free Trade Port, the Group is making comprehensive advancements in R&D, manufacturing, and other key areas:

Robust R&D: Innovation-Driven High-Quality Development

In 2024, the Group's R&D investment accounted for 17.65% of revenue, significantly higher than the industry average. The Group adopts a dual-track model of independent and collaborative R&D. By establishing innovation platforms such as the Academician Zhang Qiang Workstation and the Postdoctoral Research Station, and through in-depth cooperation with institutions including the Institute of Medicinal Plant Development of the Chinese Academy of Sciences, the Group is accelerating innovative drug development with a focus on pediatric respiratory and gastrointestinal diseases. Currently, three Category 1.1 new drugs have entered the clinical stage, and the number of intellectual property patents has increased to 112. These achievements not only safeguard children's healthy growth but also lay a solid foundation for the company's sustainable development.

Smart Manufacturing: Building an Industry Benchmark

The Group's Meian Pediatric Pharmaceutical Smart Manufacturing Base commenced operations in 2024. It has introduced internationally advanced equipment and intelligent management systems, and established production lines covering tablets, capsules, granules, and orally disintegrating films, achieving full-process automation and digitalization in pharmaceutical manufacturing. Through the implementation of the World Class Manufacturing (WCM) lean production program and a digital warehousing system, both production capacity and per-capita productivity have significantly improved. The facility has been selected as an exemplary case of industrial internet application and a model enterprise for digital transformation in Hainan Province, becoming a benchmark for intelligent transformation in the pharmaceutical industry.

Future Outlook: Anchoring the "15th Five-Year Plan" and Growing Together with the Free Trade Port

At the outset of the "15th Five-Year Plan", Huluwa Pharmaceutical Group will leverage policy advantages of the Free Trade Port, such as "zero tariffs" and "low tax rates", fully capitalize on the enhanced openness brought by the customs closure operation, continuously deepen the integration of technological innovation and smart manufacturing, and accelerate the industrialization of innovative drugs. At the same time, the Group will actively expand into overseas markets such as Southeast Asia and the Middle East, promoting "Made in Hainan" onto the global stage. It is committed to becoming a guardian of children's health across the entire life cycle in China and contributing strong pharmaceutical capabilities to the development of the Hainan Free Trade Port!